{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:04Z","timestamp":1790409244821,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cluster of differentiation 38 (CD38) monoclonal antibodies, including daratumumab and isatuximab, have demonstrated clinical activity in relapsed or refractory multiple myeloma (MM). This study aims to systematically evaluate the efficacy and safety of CD38-targeted monoclonal antibodies compared with those of standard regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study searched PubMed, the Cochrane Library, Web of Science, and Embase from inception until 30 June 2025 for randomized controlled trials (RCTs) comparing CD38 antibodies (alone or in combination) with proteasome inhibitor- or immunomodulatory agent-based control regimens in adults with multiple myeloma. Two reviewers independently screened the studies, extracted data, and assessed the risk of bias (Cochrane risk of bias 2.0). Pooled risk ratios (RRs) and hazard ratios (HRs) were estimated using fixed- or random-effects models according to I\n                      <jats:sup>2<\/jats:sup>\n                      heterogeneity. Publication bias was examined using Egger\u2019s test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of eight RCTs with 2,821 patients were included. The pooled overall response rate (ORR) was significantly improved with CD38-targeted therapies (RR 1.59; 95% confidence interval [CI] 1.32\u20131.92;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). Progression\u2010free survival (PFS) was also significantly prolonged (HR 0.50; 95% CI 0.39\u20130.61;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). Subgroup analyses indicated consistent benefits across the renal function, age groups, and prior therapy lines. However, CD38-targeted therapies were associated with higher rates of non-hematologic adverse events, including infections and diarrhea.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CD38 monoclonal antibodies enhance the depth of response and prolong progression-free survival in multiple myeloma, with an acceptable safety profile, supporting their integration into treatment algorithms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1687718","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:15:22Z","timestamp":1770880522000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Cluster of differentiation 38 monoclonal antibody therapy in the treatment of multiple myeloma: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yan-Jun","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Xinxiang Central Hospital, The Fourth Clinical College of Xinxiang Medical University","place":["Xinxiang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Zhong","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Xinxiang Central Hospital, The Fourth Clinical College of Xinxiang Medical University","place":["Xinxiang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Fen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Shandong First Medical University","place":["Tai\u2019an, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Xinxiang Central Hospital, The Fourth Clinical College of Xinxiang Medical University","place":["Xinxiang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/s0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.3389\/fimmu.2018.02559","article-title":"Perspectives for the development of CD38-Specific heavy chain antibodies as therapeutics for multiple myeloma","volume":"9","author":"Bannas","year":"2018","journal-title":"Front. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"20332","DOI":"10.1002\/cam4.6619","article-title":"Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma","volume":"12","author":"Bisht","year":"2023","journal-title":"Cancer Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/s0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1182\/blood.2020008209","article-title":"Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Dimopoulos","year":"","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/s1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"","journal-title":"Lancet Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1182\/bloodadvances.2024014139","article-title":"Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"8","author":"Ebraheem","year":"2024","journal-title":"Blood Adv."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2052658","DOI":"10.1080\/21645515.2022.2052658","article-title":"Anti CD38 monoclonal antibodies for multiple myeloma treatment","volume":"18","author":"Gozzetti","year":"2022","journal-title":"Hum. Vaccin Immunother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1519300","DOI":"10.3389\/fimmu.2025.1519300","article-title":"Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects","volume":"16","author":"Horenstein","year":"2025","journal-title":"Front. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.32604\/or.2023.043647","article-title":"Development of a cell adhesion-based prognostic model for multiple myeloma: insights into chemotherapy response and potential reversal of adhesion effects","volume":"32","author":"Hu","year":"2024","journal-title":"Oncol. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.32604\/or.2024.043423","article-title":"Analysis of the role of dihydromyricetin derived from vine tea (Ampelopsis grossedentata) on multiple myeloma by activating STAT1\/RIG-I axis","volume":"32","author":"Jiang","year":"2024","journal-title":"Oncol. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1007\/s00277-022-04917-5","article-title":"Anti-CD38 antibody therapy for patients with relapsed\/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes","volume":"101","author":"Leleu","year":"2022","journal-title":"Ann. Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.3390\/ijms25116192","article-title":"Current novel targeted therapeutic strategies in multiple myeloma","volume":"25","author":"Lin","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"107068","DOI":"10.1016\/j.phrs.2024.107068","article-title":"Targeting CD38\/ADP-ribosyl cyclase as a novel therapeutic strategy for identification of three potent agonists for leukopenia treatment","volume":"200","author":"Liu","year":"2024","journal-title":"Pharmacol. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1016\/j.clml.2021.04.012","article-title":"Daratumumab, bortezomib, and dexamethasone Versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: phase 3 LEPUS (MMY3009) study","volume":"21","author":"Lu","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.3390\/cimb46050241","article-title":"The molecular mechanisms underlying the systemic effects mediated by parathormone in the context of chronic kidney disease","volume":"46","author":"Maranduca","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1182\/bloodadvances.2021006713","article-title":"Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma","volume":"6","author":"Martin","year":"2022","journal-title":"Blood Adv."},{"key":"B19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","article-title":"Daratumumab, Bortezomib, and dexamethasone Versus Bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year Follow-up of CASTOR","volume":"20","author":"Mateos","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6430","DOI":"10.1182\/bloodadvances.2023010162","article-title":"CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies","volume":"7","author":"Perez de Acha","year":"2023","journal-title":"Blood Adv."},{"key":"B22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.clml.2024.12.002","article-title":"Real-world treatment patterns and clinical outcomes in patients with multiple myeloma previously treated with lenalidomide and an Anti-CD38 monoclonal antibody","volume":"25","author":"Ramasamy","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1586\/17474086.2014.878226","article-title":"Immunotherapy for multiple myeloma","volume":"7","author":"Rosenblatt","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1186\/s12885-024-13124-6","article-title":"Clinical and immunological characteristics of high-risk double-hit multiple myeloma","volume":"24","author":"Shang","year":"2024","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B26","doi-asserted-by":"publisher","first-page":"107291","DOI":"10.1016\/j.phrs.2024.107291","article-title":"Discovery of novel FGF trap small molecules endowed with anti-myeloma activity","volume":"206","author":"Taranto","year":"2024","journal-title":"Pharmacol. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3000605211038135","DOI":"10.1177\/03000605211038135","article-title":"Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"49","author":"Wang","year":"2021","journal-title":"J. Int. Med. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2314322","DOI":"10.1080\/15384047.2024.2314322","article-title":"CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells","volume":"25","author":"Wang","year":"2024","journal-title":"Cancer Biol. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.7150\/ijbs.68148","article-title":"Regulation of CD38 on multiple myeloma and NK cells by monoclonal antibodies","volume":"18","author":"Wu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1111\/bjh.19784","article-title":"A CD38\/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and\/or refractory to anti-CD38 monoclonal antibodies","volume":"205","author":"Zabaleta","year":"2024","journal-title":"Br. J. Haematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"955","DOI":"10.32604\/or.2023.043922","article-title":"A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients","volume":"32","author":"Zhang","year":"2024","journal-title":"Oncol. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1687718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:27:26Z","timestamp":1771928846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1687718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":34,"alternative-id":["10.3389\/fphar.2025.1687718"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1687718","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"article-number":"1687718"}}